Core Insights - Medidata has extended its collaboration with Sanofi to enhance clinical research and patient care through improved processes and data management [1][4] - The partnership aims to leverage Medidata's AI-embedded platform solutions to streamline clinical workflows and reduce costs and delays in drug development [2][4] Company Overview - Medidata is a leading provider of clinical trial solutions, celebrating 25 years of innovation with over 36,000 trials and 11 million patients involved [5] - The company offers a comprehensive platform that integrates analytics-powered insights and has over 1 million registered users across approximately 2,300 customers [5] Collaboration Details - Sanofi will utilize Medidata's expertise in decentralized clinical trials, receiving consulting and operational support as part of the extended agreement [3] - The collaboration focuses on enhancing data quality, improving study design, and accelerating the clinical development process [4]

Core Insights - Medidata and Sanofi have expanded their partnership to enhance clinical research, focusing on innovation, speed to market for new therapies, and improved health outcomes globally [1][3] - The collaboration will utilize Medidata's AI-embedded platform solutions to unify clinical workflows, reduce costs, and improve trial processes [2][4] Company Overview - Medidata has been a leader in clinical trial solutions for 25 years, supporting over 36,000 trials and 11 million patients, with a user base exceeding 1 million across approximately 2,300 customers [5] - Sanofi is a global healthcare company dedicated to transforming medicine and providing life-changing treatments and vaccines to millions [7] Partnership Details - The new agreement will leverage Medidata's expertise in decentralized clinical trials and provide Sanofi with strategic consulting and operational support to streamline research processes [3][4] - The partnership aims to enhance data quality, improve study design, and elevate patient care through unified solutions tailored to Sanofi's needs [4]